Market closedNon-fractional
Inovio Pharmaceuticals/INO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Inovio Pharmaceuticals
Inovio Pharmaceuticals Inc is a United States-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Ticker
INO
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Plymouth Meeting, United States
Employees
122
Website
www.inovio.com
INO Metrics
BasicAdvanced
$284M
Market cap
-
P/E ratio
-$5.53
EPS
1.16
Beta
-
Dividend rate
Price and volume
Market cap
$284M
Beta
1.16
Financial strength
Current ratio
4.773
Quick ratio
4.622
Long term debt to equity
11.935
Total debt to equity
14.217
Interest coverage (TTM)
-112.28%
Management effectiveness
Return on assets (TTM)
-38.56%
Return on equity (TTM)
-85.09%
Valuation
Price to revenue (TTM)
345.306
Price to book
2.7
Price to tangible book (TTM)
2.7
Price to free cash flow (TTM)
-2.125
Growth
Revenue change (TTM)
-92.95%
Earnings per share change (TTM)
-52.66%
3-year revenue growth (CAGR)
-51.93%
3-year earnings per share growth (CAGR)
-24.70%
What the Analysts think about INO
Analyst Ratings
Majority rating from 6 analysts.
INO Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
-100.00%
Net income
-$30M
21.60%
Profit margin
0.00%
-100.00%
INO Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.56
-$1.56
-$1.12
-$1.31
-
Expected
-$1.74
-$1.52
-$1.27
-$1.00
-$1.10
Surprise
-10.34%
2.63%
-11.64%
30.56%
-
INO News
AllArticlesVideos
Inovio Receives Advanced Therapy Medicinal Product Certificate from European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate INO-3107
PRNewsWire·1 day ago
INOVIO to Report Second Quarter 2024 Financial Results on August 8, 2024
PRNewsWire·2 days ago
INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access Pathway
PRNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Inovio Pharmaceuticals stock?
Inovio Pharmaceuticals (INO) has a market cap of $284M as of July 27, 2024.
What is the P/E ratio for Inovio Pharmaceuticals stock?
The price to earnings (P/E) ratio for Inovio Pharmaceuticals (INO) stock is 0 as of July 27, 2024.
Does Inovio Pharmaceuticals stock pay dividends?
No, Inovio Pharmaceuticals (INO) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Inovio Pharmaceuticals dividend payment date?
Inovio Pharmaceuticals (INO) stock does not pay dividends to its shareholders.
What is the beta indicator for Inovio Pharmaceuticals?
Inovio Pharmaceuticals (INO) has a beta rating of 1.16. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Inovio Pharmaceuticals stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.